Clinical Trial Update: Genomic Outcomes of Metformin [Phase 4]

View source ↗

Summary

A Phase 4 trial assessing genomic outcomes of metformin in adults with coronary artery disease and mild cognitive impairment, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cognitive Impairment
• Coronary Artery Disease
• Hypertension
• Obesity Abdominal

Drugs mentioned

• metformin (metformin)

Snippet

Sponsor: Wake Forest University Health Sciences | Conditions: Coronary Artery Disease, Mild Cognitive Impairment | Phase 4 | Status: COMPLETED | Results posted: 2023-11-18